Welcome to our dedicated page for Galectin Therapeutics news (Ticker: GALT), a resource for investors and traders seeking the latest updates and insights on Galectin Therapeutics stock.
Galectin Therapeutics Inc. develops therapeutics that target galectin proteins, with its lead program focused on belapectin, a carbohydrate-based galectin-3 inhibitor for MASH cirrhosis and portal hypertension. Company updates commonly cover NAVIGATE clinical-trial results, biomarker analyses, medical-conference presentations, journal publications, and FDA communications related to the belapectin development program.
News also includes financial results, research and development spending, cash-resource updates, credit financing, board composition, and investor or key-opinion-leader events. Galectin has also described additional development interests in combination immunotherapy for advanced head and neck cancers and other malignancies.
Galectin Therapeutics (NASDAQ: GALT) has successfully closed a second $10 million convertible note, part of a total of $30 million raised through three notes in 2021 from Chairman Richard E. Uihlein. The unsecured notes carry a 2% annual interest, convertible at Uihlein's discretion at a price of $5.00 or 228% above prior share price. The company aims to progress its NAVIGATE trial for NASH cirrhosis and research combining belapectin with KEYTRUDA for head and neck cancer. No drug therapies for liver fibrosis or cirrhosis are currently approved, highlighting the significance of its lead drug belapectin.
Galectin Therapeutics (NASDAQ: GALT) announces that its NAVIGATE trial for NASH cirrhosis is fully underway in all originally selected countries, with full enrollment expected by mid-2022. They have engaged leading experts in oncology to explore new treatments for Head and Neck cancers. Shareholders approved all proposals, including the reelection of the Board of Directors. The company has enhanced its management team and is progressing in its global clinical trials, indicating strong commitment to develop therapies targeting galectin-3.
Galectin Therapeutics (NASDAQ: GALT) announced advancements in its oncology and NASH cirrhosis programs as of November 15, 2021. The Board approved a company-sponsored oncology program for belapectin, with strategic guidance from leading oncology experts. Financially, the company reported a net loss of $8.6 million for Q3 2021, up from $6.0 million in Q3 2020, driven by increased R&D expenses of $6.6 million. Cash reserves stand at $36.6 million, enough to cover operations through March 2023, but an additional $30-$35 million is required by then for ongoing trials.
Galectin Therapeutics (NASDAQ:GALT) announced it will present six abstracts at The Liver Meeting™ 2021, focusing on belapectin, a galectin-3 inhibitor targeting NASH cirrhosis. Key findings include new insights into belapectin’s mechanism to inhibit galectin-3, its pharmacokinetic profile in hepatic insufficiency patients, and its innovative NAVIGATE phase 2b/3 study design aimed at preventing esophageal varices in NASH cirrhosis patients. The research highlights correlations between liver tests and portal hypertension, emphasizing the profound impact of NASH cirrhosis on quality of life.
Galectin Therapeutics (NASDAQ: GALT) announced the presentation of six scientific abstracts at The Liver Meeting™ 2021 from November 12-15. These abstracts cover new insights into belapectin, a galectin-3 inhibitor targeting NASH cirrhosis, showcasing its mechanism of action, pharmacokinetic profile in hepatic insufficiency, and innovative NAVIGATE trial design aimed at preventing esophageal varices. The research highlights the correlation between liver tests and portal hypertension, and emphasizes the impact of NASH cirrhosis on patients' quality of life.
Galectin Therapeutics (NASDAQ: GALT) announced its participation in the H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021. Dr. Pol F. Boudes, Chief Medical Officer, will engage in a fireside chat with analyst Ed Arce at 11:00 AM ET. The event aims to discuss the company's lead drug, Belapectin, which targets galectin-3 for treating liver fibrosis associated with NASH. The NAVIGATE trial is ongoing to evaluate Belapectin's efficacy in preventing esophageal varices in NASH cirrhosis patients. Live webcast will be available on the company's website.
Galectin Therapeutics Inc. (NASDAQ: GALT) announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference, scheduled for September 13-15, 2021. The company’s management will present and conduct 1-on-1 investor meetings. Investors can access the presentation starting September 13 at 7:00 A.M. ET through an online link. Galectin's leading drug, belapectin (GR-MD-02), targets galectin-3 and shows promise in treating non-alcoholic steatohepatitis (NASH) and related liver fibrosis. Belapectin is involved in ongoing clinical studies, including the NAVIGATE trial.
Galectin Therapeutics (NASDAQ:GALT) announced a $20 million convertible debt financing with Chairman Richard E. Uihlein, enhancing financial support following a $10 million deal in April. The arrangement includes two $10 million notes, the first funded on September 17, 2021, and the second by December 17, 2021. The 2% interest rate accrues additional payments based on potential share conversion. Uihlein expressed commitment to addressing unmet medical needs, specifically in NASH cirrhosis and advanced melanoma treatments, bolstered by positive Phase 1 trial results with belapectin and KEYTRUDA.
Galectin Therapeutics, Inc. (NASDAQ: GALT) announced that its management will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The virtual conference will include a presentation starting at 7:00 A.M. (ET) on September 13, along with 1-on-1 meetings with investors. Galectin's lead drug, belapectin, targets galectin-3, which is linked to diseases such as NASH and fibrosis. The NAVIGATE trial for belapectin in preventing esophageal varices in NASH cirrhosis is ongoing. More details can be found on their official website.
Galectin Therapeutics (NASDAQ:GALT) announced key leadership appointments to strengthen its management team, including Dakshina Reddy as Executive Director of Regulatory Affairs and Ezra R. Lowe, Ph.D., as Executive Director of Clinical and Preclinical Pharmacology. These changes aim to enhance the company's efforts in cancer immunotherapy and NASH cirrhosis treatments. CEO Joel Lewis emphasized that these experienced hires will facilitate advancement in clinical trials, particularly for their lead drug, belapectin, which targets galectin-3 and is involved in pivotal studies like the NAVIGATE trial.